106 results about "Ciclosporins" patented technology

The invention relates to the technical field of aplastic anemia (AA) treatment research, discloses a biomarker method for predicting the curative effect of cyclosporine on aplastic anemia, and aims to detect plasma differential metabolites of patients with aplastic anemia by adopting a metabonomics technology, find potential biomarkers for treating AA patients and find the curative effect of cyclosporine on the AA patients. CsA) is used for treating the in-vivo metabolism of AA. The method is based on liquid chromatography-mass spectrometry (LC-MS) and gas chromatography-mass spectrometry (GC-MS) technologies, and comprises the following steps: collecting 5 plasma samples of AA patients, 5 plasma samples of healthy people and 5 plasma samples of patients in a stable period after treatment for comparative analysis; and screening differential compounds by adopting a multivariate statistical method, and further performing enrichment analysis on differential metabolites. Research of the method shows that in-vivo metabolites of AA patients and healthy people are obviously different, and the way related to immunity and energy metabolism may be a key target for treating AA; csA intervenes the occurrence and development of AA by regulating and controlling immune-related metabolic ways.

The invention discloses a method for detecting the concentration of cyclosporine in blood through fluorescence and electrochemical double signals, and belongs to the technical field of biochemical analysis and medical detection. Aiming at the technical problems of insufficient sensitivity and high false positive rate of traditional single-signal detection of blood concentration of cyclosporine, the method comprises the following steps: activating carboxyl microspheres by a coupling agent, fixing double-stranded DNA (deoxyribonucleic acid) formed by a cyclosporine aptamer and an initiator chain, inducing the initiator to release by using a cyclosporine sample, realizing strand displacement through an A2-PEI composite system, and detecting the blood concentration of cyclosporine by using an A < 2 >-PEI composite system. DNA modified cadmium telluride quantum dots are respectively adopted to detect fluorescence signals, eATRP electrochemical signal amplification is carried out to detect electrochemical signals, concentration values obtained by the two signals are verified, and an average value is taken as a result. The method can accurately capture low-concentration cyclosporine signals in blood, eliminates interference of a single method, is mainly used for accurately monitoring the blood concentration of cyclosporine, and provides a reliable detection means for medication safety and curative effect control of cyclosporine in clinical scenes such as organ transplantation.

A method of preparing patients for cataract surgery includes topical administration of a cyclosporine solution. The administration may occur twice daily and may occur over the course of 28 days. The method results in an improved error prediction for 1-month spherical equivalent refractive outcome and improved ocular surface irregularity.

The invention relates to a preparation method of an active oxygen responsive microneedle with a separable base, which comprises the following steps: mixing 3-(acrylamide) phenylboronic acid, epigallocatechin gallate and N-vinyl pyrrolidone, and standing to obtain an E-A compound solution; dissolving cyclosporine and an initiator in the E-A compound solution to obtain a microneedle precursor solution; placing the microneedle precursor solution on the surface of a microneedle mold, and performing in-situ polymerization to form a microneedle body; paving a mixed aqueous solution of poly (N-isopropylacrylamide-n-butyl acrylate) and polyvinyl alcohol on the microneedle mold substrate forming the microneedle body, and drying to form a microneedle substrate; and stripping the microneedle body with the microneedle substrate from the microneedle mold to obtain the active oxygen responsive microneedle with the separable base. According to the product prepared by the preparation method, drug release can be adjusted by sensing ROS of an inflammation part, deep penetration of the drug is realized, controllable separation between a backing layer and a needle head can be realized, and discomfort of a patient is reduced.

The invention relates to the field of biological medicine, in particular to a carrier-free nanoparticle which is formed by self-assembly of cyclosporine A and costunolide through intermolecular weak interaction. The invention also provides a preparation method of the traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of medicines for treating xerophthalmia. The carrier-free nano eye drops based on the synergistic effect of Chinese and western medicines are used for anti-inflammatory treatment of the xerophthalmia, a new strategy is provided for precise diagnosis and treatment of the xerophthalmia, the problems of single target spot, limited curative effect and the like in traditional treatment are solved, and more efficient inflammation control is expected to be achieved. While the curative effect is improved, the tolerance risk caused by long-term use is reduced, double optimization of the curative effect and safety is realized, and the limitation of traditional single drug treatment is broken through. By adopting the carrier-free nano preparation, the delivery efficiency of the medicine on the ocular surface is effectively improved, the bioavailability is enhanced, powerful support is provided for improving the curative effect of the medicine, and the carrier limitation bottleneck is broken through.

Disclosed herein are methods of using cyclosporine A ophthalmic gel in treating moderate to severe dry eye disease.

The invention provides pharmaceutical compositions comprising about 0.05 to 0.1% (w / v) cyclosporine dissolved in 1-perfluorobutyl-pentane for use in the topical treatment of dry eye disease and provides for dosing and treatment methods thereof. The invention further provides kits comprising such compositions.

The invention relates to an ophthalmic composition in an aqueous solution form. The ophthalmic composition consists of cyclosporine, medium chain triglyceride, polyoxyethylene (40) hydrogenated castor oil, polyethylene glycol 400, glycerol, sodium acetate and water. The pH value of the ophthalmic composition is close to that of tears, and the ophthalmic composition is good in medication comfort and good in stability during storage.

The present invention relates to a stable nanomicellar ophthalmic formulation comprising cyclosporine, hydrogenated 40 polyoxyl castor oil, octoxynol-40, and an aqueous vehicle, wherein the stable nanomicellar ophthalmic formulation is made by a method comprising: a) mixing the hydrogenated 40 polyoxyl castor oil and the octoxynol-40, wherein the mixing produces a Mixture A comprising a water content of less than 3%; b) adding the cyclosporine to the Mixture A to form a Mixture B; and c) mixing the Mixture B with the aqueous vehicle, thereby forming the stable nanomicellar ophthalmic formulation.

The invention discloses difunctional nano drug-loaded eye drops for xerophthalmia and a preparation method of the difunctional nano drug-loaded eye drops, and belongs to the field of pharmaceutical preparation technologies and ophthalmology pharmacy. The core of the invention is to construct a composite nanoparticle which has a core-shell structure and has long-acting adhesion lubrication and targeted control drug release functions. The preparation method comprises the following steps: firstly, encapsulating a hydrophobic immunosuppressant such as cyclosporine A in a biodegradable pad polymer matrix such as polylactic acid-glycolic acid copolymer (PLGA) by an emulsification-solvent evaporation method to form a drug-loaded polymer nano core; through the exquisite integrated design of the structure and the function, collaborative targeted therapy of two core pathological links of'tear film instability 'and'immune inflammation' of xerophthalmia is achieved, the bioavailability of the medicine is remarkably improved, the medication frequency and eye irritation are reduced, and the curative effect of xerophthalmia is improved. A more efficient and safer administration scheme with better patient compliance is provided for clinical treatment of xerophthalmia.

Compositions are disclosed that include acridinium esters of cyclosporin A or C. Kits containing same, as well as methods of making and using same, are also disclosed.

The present disclosure relates to oral compositions of Compound I or its derivatives. Several dosage ranges are disclosed, along with SAD, MAD, and PK data. Comparative data between Compound I, tofacitinib, ritrecitinib, and cyclosporin A are also disclosed. Methods of use for treating inflammatory conditions are also disclosed.

The invention relates to cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection. In particular, the invention provides a cyclosporine liquid formulation for use as an aerosol for inhalation in a method of preventing or treating pulmonary chronic graft rejection in single lung transplanted patients. The formulation is preferably administered once or twice daily. The formulation may be aerosolized with a nebulizer that comprises features for monitoring the time, date and duration of inhalation by the patient, in order to monitor patient adherence. The formulation according to the invention may be combined with standard immunosuppressants and corticosteroids.

The embodiment of the invention discloses a pharmaceutical composition for improving cell therapy regeneration and application thereof. The pharmaceutical composition comprises 5 to 15 ng / mL of a transforming growth factor beta, 0.02 to 0.06 [mu] M of triptolide, 8 to 12 ng / mL of a vascular endothelial growth factor, 0.1 to 1 [mu] g / mL of a grape seed extract, 0.8 to 1.6 mg / mL of a trace element solution, 0.5 to 2% of hyaluronic acid, 0.05 to 0.15 [mu] M of cyclosporin and 15 to 25 mM of an HEPES buffer solution. The pharmaceutical composition provided by the invention can effectively promote proliferation and differentiation of hair follicle-derived mesenchymal stem cells, plays a better role in treating alopecia, has the advantages of small side effect, high safety, lower cost and wide applicable crowd, and has better application prospects in clinic.

The invention relates to the technical field of hematopoietic reconstruction, in particular to application of costal cartilage derived stem cells and costal cartilage derived stem cells combined with pluripotent progenitor cells, hematopoietic stem cells or cyclosporine in preparation of a preparation for hematopoietic reconstruction. The costal cartilage derived stem cells (CD45-CD51 +) are derived from costal cartilage and have remarkable ecological niche recovery capability. When the cells are used alone or combined with hematopoietic stem cells and pluripotent progenitor cells, the hematopoietic function can be enhanced. The costal cartilage-derived stem cells are directionally differentiated into important supporting cells forming bone marrow ecological niche, secrete hematopoietic cell factors and protect hematopoietic stem / progenitor cells. In treatment of aplastic anemia, costal cartilage-derived stem cells and cyclosporin A have a synergistic effect, and immune-mediated bone marrow failure is improved through dual mechanisms. According to the technical scheme, the technical problem that the effect of treating bone marrow failure and promoting hematopoietic reconstruction by hematopoietic stem cell transplantation is not ideal is solved, and a new way is opened up for treating bone marrow failure and blood system diseases.

A method of preparing an implantable biomaterial includes combining a polymer with a neuro-regenerative agent or immunosuppressive agent selected from a group comprising at least one of: rapamycin, cyclosporine A, or analogs thereof, melting the polymer, and extruding the polymer and the neuro-regenerative agent or immunosuppressive agent to form the implantable biomaterial.

The present invention aims to provide a cyclosporine self-microemulsion preparation, its preparation method and application. The preparation is composed of cyclosporine, α-tocopherol, amino acids, a solvent, a surfactant, and a co-surfactant. This cyclosporine preparation has good stability and palatability. While effectively improving the bioavailability of the active ingredient, it also improves the stability and palatability of the cyclosporine preparation. After oral administration, under the action of the gastrointestinal tract, the preparation is first dispersed and diluted by gastric juice to form a microemulsion, and then digested by digestive enzymes, etc., and has obvious effects in the treatment of canine and feline atopic dermatitis or allergic dermatitis, etc.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to a W / O / W ophthalmic composite emulsion composition and a preparation method thereof. The raw material components comprise atropine sulfate, cyclosporin, sodium hyaluronate, castor oil, Tween 80, hydroxypropyl methylcellulose, sodium chloride, sodium oxide, hydrogen chloride and distilled water. The atropine sulfate is encapsulated in the W / O / W type composite emulsion droplet, the pH value of an internal water layer of the composite emulsion droplet is adjusted to 3.8-4.5 so as to improve the stability of the atropine sulfate, and the pH value of an external water layer of the composite emulsion droplet is adjusted to 6.5-7.5 so as to improve the comfort of eye medication. The prepared composite emulsion has the advantages of being fast in absorption, high in bioavailability, capable of improving drug stability and the like.

The invention provides a medicine for preventing or treating enteritis. Hamp is adopted; and E, dyeing, determination of IL-6 factors in serum of each group of animals and the like are used for researching the influence of the vocyclosporine on intestinal tissues, mucosal barriers and immune systems of DSS or TNBS-induced mouse colitis models. Experimental basis is provided for clinical application of the vocyclosporine in preparation of the colitis treatment medicine, and the vocyclosporine has good application prospects and huge potential value and social significance.

The present disclosure relates to solid state forms of Voclosporin and salts thereof, processes for preparation thereof and pharmaceutical compositions thereof.

The utility model relates to the technical field of mass spectrometers, and discloses a mass spectrometer for detecting the concentration of cyclosporine A in human whole blood, which comprises a sampler, a fixed box is fixedly mounted at the bottom of an inner cavity of the sampler, a through hole is formed in the upper part of an inner cavity of the fixed box, a motor is fixedly mounted at the rear part of the inner cavity of the fixed box, and a through hole is formed in the inner cavity of the fixed box. A first gear is fixedly connected to an output shaft of the motor in a sleeving mode, a gear ring is meshed with the outer edge of the first gear, edge rings are fixedly installed on the upper portion and the lower portion of the gear ring respectively, a sliding groove is formed in an inner cavity of the fixing box, a tooth groove is formed in an inner cavity of the gear ring, second gears are evenly meshed with the outer edge of the tooth groove, and a rotating shaft is fixedly connected to the middle of the second gears in a sleeving mode; the stroke of a motor is adjusted through a pressure sensor, sample bottles are fixed through a clamping plate, the device can conveniently fix the sample bottles with different sizes, the practicability of the device is improved, the situation that the air tightness is affected by shaking of the sample bottles is avoided, and the accuracy of a detection result is guaranteed.

The present invention discloses a composition for treating gynecological diseases, a preparation method and an application thereof, and specifically relates to the field of medical technology. The composition comprises placental mesenchymal stem cells (PMSCs) extract, vitamin C, cyclosporine, an amino acid mixture and sodium hyaluronate. The composition of the present invention utilizes a multi-factor secretion extraction mixture to perform rehabilitation treatment on cervicitis and cervical erosion, that is, utilizes factors to regulate and repair inflammation, does not require customized treatment, and can meet the needs of almost all patients, even for patients with multiple underlying diseases, without worrying about adverse reactions after use.

The invention discloses a stable cyclosporine ophthalmic ultra-micro emulsion, which comprises 0.1% of cyclosporine, 1%-2% of medium chain triglyceride, 0.4%-0.8% of an emulsifier, 2%-3% of glycerol, 0.0005%-0.005% of sitaammonium chloride and sodium hydroxide with a required amount for adjusting the pH value of the emulsion to 6.1-7.9, and the emulsifier is a combination of teloxaben and poloxamer in a weight ratio of 3: 1. The cyclosporin ophthalmic ultra-micro emulsion provided by the invention is smaller in droplet particle size and higher in Zeta potential, is basically not changed after being placed for a long time, and has better stability and better expected drug effect.

Methods, compositions, and kits suitable for use in the prevention, treatment, or recovery of fibrosis are disclosed. [Solution] The above problems are solved by a method comprising administering a composition comprising a cyclosporine analog (e.g., CRV431) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof to a subject requiring prevention, treatment, or recovery from fibrosis, and by compositions and kits for the prevention, treatment, or recovery from fibrosis comprising a cyclosporine analog (e.g., CRV431) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

To provide novel cyclosporin derivatives.SOLUTION: Provided is a compound having the following structure or a pharmaceutically acceptable salt thereof. Also provided are a pharmaceutical composition comprising the same, and a method that uses the same for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, lung, liver, and kidney diseases, and hair loss.SELECTED DRAWING: None

Disclosed herein are cyclosporine compounds and methods for use in the treatment or prevention of neutrophil-mediated inflammation, wherein the compounds inhibit the activity of MRP2 and FPR1.

The invention relates to the field of pharmaceutical preparations, in particular to a cyclosporine ophthalmic preparation and a preparation method and application thereof. The preparation comprises cyclosporin, an oil phase, a surfactant, a cosurfactant, a thickening agent, an osmotic pressure regulator and water for injection. By controlling the peroxide value ratio of the oil phase to the cosurfactant or the pH value of the cosurfactant, the ophthalmic preparation containing high-concentration cyclosporin is controllable in quality, stable and feasible.

The invention discloses a composition. The composition is a combination of any two or three of cyclosporine A, allipovir, allipovir and [MeIle] 4-cyclosporine. The invention also discloses the cyclosporin A, the allipovir, the allipovir, the [MeIle] 4-cyclosporin and the application of the composition in preparation of a preparation for inhibiting proliferation of the African swine fever virus. The medicine has an application prospect.

The application belongs to the field of ophthalmic nano-preparations, and particularly relates to an ophthalmic poly-nitrogen-oxygen amphoteric nano-drug carrier, an ophthalmic nano-preparation and a use. The nano-drug carrier is prepared by using a random copolymer of 2-(N-oxide-N,N-diethylamino)ethyl methacrylate and butyl methacrylate, has an average particle size of 7-12 nm, and can be used for loading ophthalmic drugs such as cyclosporine A. Research shows that the nano-drug carrier has good corneal retention characteristics and corneal permeability, and after loading cyclosporine A, has a good relieving effect on corneal damage and local inflammation of dry eye model animals, and the safety of the nano-drug carrier is good, and the nano-drug carrier has a good application prospect.